Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Zentalis Pharmaceuticals, Inc. (ZNTL) had Return on Investments of -63.39% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-137.06M |
|
-- |
|
-- |
|
$152.81M |
|
$-152.81M |
|
$16.19M |
|
$-136.62M |
|
$-136.62M |
|
$-137.06M |
|
$-137.06M |
|
$-137.06M |
|
$-137.06M |
|
$-152.81M |
|
$-154.83M |
|
71.87M |
|
71.87M |
|
$-1.91 |
|
$-1.91 |
|
| Balance Sheet Financials | |
$253.19M |
|
$2.77M |
|
$35.78M |
|
$288.97M |
|
$36.56M |
|
-- |
|
$36.20M |
|
$72.76M |
|
$216.20M |
|
$216.20M |
|
$216.20M |
|
69.09M |
|
| Cash Flow Statement Financials | |
$-125.25M |
|
$131.62M |
|
$-4.28M |
|
$36.53M |
|
$38.62M |
|
$2.09M |
|
$20.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-124.55M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-63.39% |
|
-63.39% |
|
-47.43% |
|
|
Return on Investments |
-63.39% |
$3.13 |
|
$-1.73 |
|
$-1.74 |
|